Adva and Autolomous Launch Digital Pioneer Program for Cell Therapy

Adva Biotechnology Ltd. and Autolomous Ltd. have joined forces to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitizing, decentralizing, and scaling out autologous cell therapy manufacturing.

The program brings together Adva’s automated and closed-system manufacturing platform with Autolomous’ digital orchestration and manufacturing management technologies, forming an integrated solution designed to assure right-first-time production processes are developed with full data traceability and compliance, thereby reducing overall time-to-patient of life-saving therapies.

“Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model,” said Dr. Ohad Karnieli, Founder and CEO of Adva Biotechnology. “This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one.”

“Our mission is simple: to bring life-saving therapies to all patients around the world, safer, faster, and affordable. By providing a digital-first infrastructure to the industry, we are removing the barriers between innovation and the patient,” said Alexander Seyf, Co-Founder and CEO of Autolomous. “This program is a call to action, offering a foundation that will help us build the future of personalized medicine – one defined by trust, equity, and most importantly, acting for hope.”

The Digital Pioneer Program is now open for inquiries from cell therapy developers interested in adopting next-generation manufacturing technologies.